Royalty Pharma (RPRX) Long-Term Debt Issuances (2020 - 2025)

Royalty Pharma has reported Long-Term Debt Issuances for 5 years, with the latest figure at -$275.0 million in Q4 2025.

• Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$275.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$471.2 million (changed 0.0% YoY) and the FY2025 annual result came in at $1.0 billion, changed N/A from the prior year.
• Long-Term Debt Issuances declined to -$275.0 million in Q4 2025 per RPRX's latest filing, from $1.3 billion in the prior quarter.
• Over five years, Long-Term Debt Issuances peaked at $1.3 billion in Q3 2025 and troughed at -$1.5 billion in Q3 2024.
• A 4-year average of $88.1 million and a median of $362.5 million in 2023 frame the typical range for Long-Term Debt Issuances.
• The sharpest annual moves came in 2021 and 2025: Long-Term Debt Issuances sank 78.25% in 2021, then jumped 186.66% in 2025.
• Over 4 years, Long-Term Debt Issuances stood at -$1.3 billion in 2021, then soared by 178.58% to $1.0 billion in 2023, then sank by 247.12% to -$1.5 billion in 2024, then jumped by 81.31% to -$275.0 million in 2025.
• According to Business Quant data, Long-Term Debt Issuances over the past three periods registered -$275.0 million, $1.3 billion, and -$1.5 billion for Q4 2025, Q3 2025, and Q3 2024 respectively.